Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

ABSTRACT:

Introduction

The currently available anti-HIV-1 drugs can control the infection but do not eradicate the virus. Their long-term use can lead to side effects and resistance to therapy. Therefore, eradication of the virus has been a major goal of research. Biological therapeutics including broadly neutralizing monoclonal antibodies (bnAbs) are promising tools to reach this goal. They could also help design novel vaccine immunogens potentially capable of eliciting bnAbs targeting the HIV-1 envelope glycoproteins (Envs).

Areas covered

We review HIV-1 bnAbs and their potential as candidate prophylactics and therapeutics used individually, in combination, or as bispecific fusion proteins. We also discuss their potential use in the 'activation-elimination' approach for HIV-1 eradic

SUBMITTER: Chen W 

PROVIDER: S-EPMC6953398 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature